LONG FACTOR CERTIFICATE - UCB Stock

Z1B9H

DE000GP79469

Market Closed - Euronext Paris 12:30:02 2024-06-07 pm EDT
33.88 ^EUR	+3.39%

Current month	+14.87%
1 month	+69.59%

Comparison chart between the derivative product and it's underlying value

End-of-day quotes

Chart UCB

Latest news about UCB

UCB : Acquisition of own shares	May. 31	PU
UCB : Commitment to Innovation in Drug Development	May. 29	PU
UCB : announces publication in The Lancet of phase 3 bimekizumab▼ trials in moderate to severe hidradenitis suppurativa	May. 23	PU
UCB - Acquisition of own shares	May. 20	AQ

More news

Quotes 5-day view

Date	Price	Change
24-06-07	33.29	+1.59%
24-06-06	32.77	+0.74%
24-06-05	32.53	+17.39%
24-06-04	27.71	+5.44%
24-06-03	26.28	-9.32%

Real-time Euronext Paris

Last update June 07, 2024 at 12:30 pm EDT

More quotes

Static data

Product type	Exotic Products
Buy / Sell	CALL
Underlying	UCB
Issuer	Goldman Sachs
	Z1B9H
ISIN	DE000GP79469
Date issued	2023-06-28
Strike	120 €
Maturity	Unlimited
Parity	0.32 : 1
Emission price	9.97 €
Emission volume	N/A
Settlement	cash
Currency	EUR

Technical Indicators

Highest since issue	37.78 €
Lowest since issue	0.13 €
Spread	1.5 €
Spread %	4.35%

Company Profile

UCB is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system.

Sector

More about the company

Ratings for UCB

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Consensus: UCB

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

130 EUR

Average target price

126.4 EUR

Spread / Average Target

-2.78%

Consensus